Interstitial cystitis, also called bladder pain syndrome, has no single known cause. Instead, it appears to result from several overlapping problems: a damaged bladder lining, an overactive immune response, hypersensitive nerves, and possibly a genetic predisposition. The condition affects 3 to 8 million women and 1 to 4 million men in the United States, with symptoms typically appearing around age 33 and a formal diagnosis following about six years later, around age 39.
A Damaged Bladder Lining
The inside of your bladder is coated with a protective layer of sugar-like molecules called glycosaminoglycans, or GAGs. This layer acts as a barrier, keeping the irritating chemicals in urine from reaching the bladder wall’s deeper tissue and nerve endings. In people with interstitial cystitis, this barrier is compromised. The protective coating breaks down, and substances like potassium and urea seep through into the bladder wall. Studies have shown that people with interstitial cystitis absorb over six times as much urea through the bladder wall compared to people without the condition. Potassium ions in particular trigger pain when they reach the exposed tissue, while sodium ions at the same concentration do not.
What makes this damage self-perpetuating is a molecule called antiproliferative factor, or APF. Bladder cells from people with interstitial cystitis produce this protein, and healthy bladder cells do not. APF powerfully slows down the growth of new bladder lining cells, even in tiny concentrations. It also reduces production of a growth factor that bladder cells need to multiply during repair. The result is a bladder lining that can’t heal itself properly. As the barrier stays thin and leaky, irritants in urine continue reaching nerve endings and triggering pain, urgency, and frequency. This cycle of damage and failed repair is considered one of the central mechanisms driving the condition.
Immune System Overactivity
A significant subset of people with interstitial cystitis have unusually high numbers of mast cells in their bladder walls. Mast cells are immune cells that release chemicals involved in inflammation, pain signaling, and blood vessel dilation. In a healthy bladder, mast cells are present in small numbers. In interstitial cystitis, they accumulate in the bladder tissue and become activated, releasing their contents into the surrounding area.
This mast cell buildup and the breakdown of the protective bladder lining likely work together. A leaky lining lets irritants through, which may trigger mast cells. Activated mast cells then release inflammatory chemicals that cause further tissue damage, swelling, and pain. The two problems reinforce each other, creating a self-sustaining inflammatory loop that helps explain why interstitial cystitis is chronic rather than something that resolves on its own.
Nerve Sensitization and Chronic Pain
Over time, the nerves in and around the bladder undergo changes that amplify pain and urinary urgency. When the bladder stretches, its lining cells release a signaling molecule (ATP) that activates pain-sensing nerve fibers. In interstitial cystitis, this signaling system becomes overactive. The nerves themselves become more sensitive, responding to lower levels of stimulation than they normally would.
This sensitization doesn’t stay local. Research in animal models of chronic cystitis shows that nerve cells in the spinal cord also become upregulated, meaning the spinal cord itself starts amplifying pain signals from the bladder. This is called central sensitization, and it’s the same process that drives chronic pain in conditions like fibromyalgia. It helps explain why some people with interstitial cystitis experience pain even when their bladder is relatively empty, or why pain can spread to the broader pelvic region. The nervous system has essentially turned up its volume dial and left it there.
Two Distinct Subtypes
Not everyone with interstitial cystitis has the same disease process. There are two recognized subtypes, and the distinction matters because they behave differently.
Some patients have visible inflammatory lesions on the bladder wall, known as Hunner’s lesions. Reported prevalence of this subtype ranges widely, from 5% to 57% of interstitial cystitis patients depending on the study and how thoroughly clinicians look for them. These lesions represent areas of intense, concentrated inflammation and are the only cystoscopic finding that definitively points to interstitial cystitis.
The remaining patients have non-ulcerative interstitial cystitis, where the bladder may look relatively normal on examination or show only pinpoint hemorrhages (glomerulations) that can also appear in other conditions or even in people without symptoms. These two groups are considered clinically and pathologically distinct, which suggests different underlying mechanisms may dominate in each subtype.
Genetic Factors
Interstitial cystitis runs in some families, and genetic research has begun to identify why. A genome-wide linkage study of affected families found significant evidence for a genetic variant on chromosome 3, with additional suggestive links on chromosomes 1, 4, 9, and 14. The inheritance pattern in the studied families fit a dominant model, meaning a single copy of a risk variant from one parent could be enough to increase susceptibility. Pedigrees in the study included families with up to 12 affected members across generations.
These findings don’t mean a single gene causes interstitial cystitis. Rather, inherited variants likely create a vulnerability, perhaps by affecting how the bladder lining develops, how the immune system responds to irritation, or how nerves process pain signals. Environmental triggers then push a genetically susceptible person toward developing the condition.
The Autoimmune Question
People with interstitial cystitis are often diagnosed with other chronic conditions, and population studies have noted higher rates of rheumatoid arthritis, lupus, Sjögren’s syndrome, and inflammatory bowel disease among them. This overlap has fueled speculation that interstitial cystitis might be autoimmune in nature.
However, a large genetic analysis (a Mendelian randomization study examining 14 autoimmune diseases) found that only asthma showed a statistically significant causal relationship with interstitial cystitis. People genetically predisposed to asthma had roughly 69% higher odds of developing the condition. None of the other autoimmune diseases examined, including lupus, rheumatoid arthritis, Sjögren’s syndrome, celiac disease, or multiple sclerosis, showed a causal link. This suggests that while interstitial cystitis and autoimmune conditions frequently coexist, most of them likely share common risk factors rather than directly causing one another. The asthma connection is intriguing because asthma also involves mast cell activation, hinting at shared immune pathways between the two conditions.
How These Factors Work Together
The most accurate way to think about interstitial cystitis is as a syndrome with multiple contributing causes that vary from person to person. In one patient, a leaky bladder lining and impaired repair may be the dominant problem. In another, mast cell activation drives the inflammation. In many, several of these factors operate simultaneously and reinforce each other: genetic susceptibility creates a vulnerable bladder lining, damage lets irritants through, mast cells respond with inflammation, and the nervous system gradually becomes sensitized to pain.
This is why diagnosis relies on symptoms and the exclusion of other conditions rather than a definitive test. The American Urological Association recommends a careful history, physical exam, and lab work, with cystoscopy reserved for cases where the diagnosis is uncertain. There is no single biomarker, no imaging finding, and no lab value that confirms the condition in all patients. The potassium sensitivity test, once used to detect a leaky bladder lining, is no longer recommended because it lacks the accuracy to reliably guide clinical decisions.